Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00565006
First received: November 27, 2007
Last updated: February 25, 2015
Last verified: February 2015
History of Changes

November 27, 2007
February 25, 2015
July 2006
September 2006   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00565006 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)
Not Provided

This study will investigate the influence of MK0859 on ambulatory blood pressure, and how safe and tolerable MK0859 is on the subjects This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Not Provided
Interventional
Phase 1
Not Provided
Ambulatory Blood Pressure
Drug: MK0859
Not Provided
Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007 Dec 8;370(9603):1907-14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
September 2006
September 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • You are between the ages of 45-75
  • You are a man or non-pregnant woman
  • You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication

Exclusion Criteria:

  • You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months
  • You have used St. John's Wort or any products that include it within the last 2 weeks
  • You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks
  • You have a history of drug allergies (anaphylaxis, angioedema)
  • You have taken an investigational drug in another clinical trial within the last 4 weeks
  • You have a history of cardiovascular disease including hypertension (high blood pressure)
  • You have a history of renal disease
  • You have a history of gall bladder disease or have had abnormal liver function tests
  • You have a history of drug or alcohol abuse
  • You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)
Both
45 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00565006
0859-012, 2007_656
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP